‌

US Patent 11891388 Pyrazolopyridine compounds and uses thereof

Patent 11891388 was granted and assigned to Incyte on February, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Alexander Sokolsky0

Hai Fen Ye0

Qinda Ye0

Wenqing Yao0

Kai Liu0

Oleg Vechorkin0

Jun Pan0

Date of Patent

February 6, 2024

0

Patent Application Number

175588240

Date Filed

December 22, 2021

0

Patent Citations

US Patent 7429609 Pyrazole compound and medicinal composition containing the same

0

US Patent 6916927 Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction

0

US Patent 7105532 Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors

0

US Patent 7166293 Angiogenesis inhibitors

0

US Patent 7259165 Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands

0

US Patent 7345178 Sirtuin modulating compounds

0

US Patent 10752635 Indazole compounds and uses thereof

0

US Patent 10800761 Carboxamide compounds and uses thereof

0

...

Patent Primary Examiner

Niloofar Rahmani

0

CPC Code

0

Patent abstract

Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11891388 Pyrazolopyridine compounds and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.